newsfilter
← Latest News
GlobeNewswire·

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

  • Madrigal Pharmaceuticals granted equity inducement awards to ten new non-executive employees on August 1, 2026, under its 2025 Inducement Plan.
  • The Compensation Committee approved the 4,263 total time-based restricted stock units as inducement material for employment acceptance.
  • All restricted stock units vest in four equal installments on the first through fourth anniversaries of the grant date, contingent on continued employment.
  • Madrigal Pharmaceuticals is a biopharmaceutical company focused on novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).
  • The company's medication Rezdiffra (resmetirom) is the first FDA & European Commission approved treatment for MASH with moderate to advanced fibrosis.
  • An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).